Clinical Trial Update: Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma [Phase 3]

View source ↗

Summary

Phase 3 trial of Recombinant Human Relaxin for diffuse scleroderma (systemic sclerosis) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Recombinant Human Relaxin (relaxin)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Systemic Sclerosis | Phase 3 | Status: COMPLETED